The Experts below are selected from a list of 7092 Experts worldwide ranked by ideXlab platform
Jiangfeng Huang - One of the best experts on this subject based on the ideXlab platform.
-
overproduction of native endo β 1 4 glucanases leads to largely enhanced biomass saccharification and bioethanol production by specific modification of cellulose features in transgenic rice
Biotechnology for Biofuels, 2019Co-Authors: Jiangfeng Huang, Tao Xia, Yanting Wang, Youmei Wang, Yuanyuan Chen, Guosheng Xie, Fengwu Bai, Liangcai PengAbstract:Genetic modification of Plant cell walls has been implemented to reduce lignocellulosic recalcitrance for biofuel production. Plant Glycoside hydrolase family 9 (GH9) comprises endo-β-1,4-glucanase in Plants. Few studies have examined the roles of GH9 in cell wall modification. In this study, we independently overexpressed two genes from GH9B subclasses (OsGH9B1 and OsGH9B3) and examined cell wall features and biomass saccharification in transgenic rice Plants. Compared with the wild type (WT, Nipponbare), the OsGH9B1 and OsGH9B3 transgenic rice Plants, respectively, contained much higher OsGH9B1 and OsGH9B3 protein levels and both proteins were observed in situ with nonspecific distribution in the Plant cells. The transgenic lines exhibited significantly increased cellulase activity in vitro than the WT. The OsGH9B1 and OsGH9B3 transgenic Plants showed a slight alteration in three wall polymer compositions (cellulose, hemicelluloses, and lignin), in their stem mechanical strength and biomass yield, but were significantly decreased in the cellulose degree of polymerization (DP) and lignocellulose crystalline index (CrI) by 21–22%. Notably, the crude cellulose substrates of the transgenic lines were more efficiently digested by cellobiohydrolase (CBHI) than those of the WT, indicating the significantly increased amounts of reducing ends of β-1,4-glucans in cellulose microfibrils. Finally, the engineered lines generated high sugar yields after mild alkali pretreatments and subsequent enzymatic hydrolysis, resulting in the high bioethanol yields obtained at 22.5% of dry matter. Overproduction of OsGH9B1/B3 enzymes should have specific activity in the postmodification of cellulose microfibrils. The increased reducing ends of β-1,4-glucan chains for reduced cellulose DP and CrI positively affected biomass enzymatic saccharification. Our results demonstrate a potential strategy for genetic modification of cellulose microfibrils in bioenergy crops.
-
Overproduction of native endo-β-1,4-glucanases leads to largely enhanced biomass saccharification and bioethanol production by specific modification of cellulose features in transgenic rice
BMC, 2019Co-Authors: Jiangfeng Huang, Tao Xia, Yanting Wang, Youmei Wang, Yuanyuan Chen, Guosheng Xie, Fengwu BaiAbstract:Abstract Background Genetic modification of Plant cell walls has been implemented to reduce lignocellulosic recalcitrance for biofuel production. Plant Glycoside hydrolase family 9 (GH9) comprises endo-β-1,4-glucanase in Plants. Few studies have examined the roles of GH9 in cell wall modification. In this study, we independently overexpressed two genes from GH9B subclasses (OsGH9B1 and OsGH9B3) and examined cell wall features and biomass saccharification in transgenic rice Plants. Results Compared with the wild type (WT, Nipponbare), the OsGH9B1 and OsGH9B3 transgenic rice Plants, respectively, contained much higher OsGH9B1 and OsGH9B3 protein levels and both proteins were observed in situ with nonspecific distribution in the Plant cells. The transgenic lines exhibited significantly increased cellulase activity in vitro than the WT. The OsGH9B1 and OsGH9B3 transgenic Plants showed a slight alteration in three wall polymer compositions (cellulose, hemicelluloses, and lignin), in their stem mechanical strength and biomass yield, but were significantly decreased in the cellulose degree of polymerization (DP) and lignocellulose crystalline index (CrI) by 21–22%. Notably, the crude cellulose substrates of the transgenic lines were more efficiently digested by cellobiohydrolase (CBHI) than those of the WT, indicating the significantly increased amounts of reducing ends of β-1,4-glucans in cellulose microfibrils. Finally, the engineered lines generated high sugar yields after mild alkali pretreatments and subsequent enzymatic hydrolysis, resulting in the high bioethanol yields obtained at 22.5% of dry matter. Conclusions Overproduction of OsGH9B1/B3 enzymes should have specific activity in the postmodification of cellulose microfibrils. The increased reducing ends of β-1,4-glucan chains for reduced cellulose DP and CrI positively affected biomass enzymatic saccharification. Our results demonstrate a potential strategy for genetic modification of cellulose microfibrils in bioenergy crops
Juei-tang Cheng - One of the best experts on this subject based on the ideXlab platform.
-
a double blind placebo controlled study of the effectiveness and tolerability of oral stevioside in human hypertension
British Journal of Clinical Pharmacology, 2001Co-Authors: Paul K S Chan, Brian Tomlinson, Ming Hsiung Hsieh, Yi Jen Chen, Juei-tang ChengAbstract:Aims Stevioside is a natural Plant Glycoside isolated from the Plant Stevia rebaudiana which has been commercialized as a sweetener in Japan for more than 20 years. Previous animal studies have shown that stevioside has an antihypertensive effect. This study was to designed to evaluate the effect of stevioside in human hypertension. Methods A multicentre, randomized, double-blind, placebo-controlled study was undertaken. This study group consisted of 106 Chinese hypertensive subjects with diastolic blood pressure between 95 and 110 mmHg and ages ranging from 28 to 75 years with 60 subjects (men 34, women 26; mean t s.d., 54.1t3.8 years) allocated to active treatment and 46 (men 19, women 27; mean t s.d., 53.7t4.1 years) to placebo treatment. Each subject was given capsules containing stevioside (250 mg) or placebo thrice daily and followed-up at monthly intervals for 1 year. Results After 3 months, the systolic and diastolic blood pressure of the stevioside group decreased significantly (systolic: 166.0t9.4‐152.6t6.8 mmHg; diastolic: 104.7t5.2‐90.3t3.6 mmHg, P<0.05), and the effect persisted during the whole year. Blood biochemistry parameters including lipid and glucose showed no significant changes. No significant adverse effect was observed and quality of life assessment showed no deterioration. Conclusions This study shows that oral stevioside is a well tolerated and effective modality that may be considered as an alternative or supplementary therapy for patients with hypertension.
-
a double blind placebo controlled study of the effectiveness and tolerability of oral stevioside in human hypertension
British Journal of Clinical Pharmacology, 2001Co-Authors: Paul K S Chan, Brian Tomlinson, Ming Hsiung Hsieh, Yi Jen Chen, Juei-tang ChengAbstract:Aims Stevioside is a natural Plant Glycoside isolated from the Plant Stevia rebaudiana which has been commercialized as a sweetener in Japan for more than 20 years. Previous animal studies have shown that stevioside has an antihypertensive effect. This study was to designed to evaluate the effect of stevioside in human hypertension. Methods A multicentre, randomized, double-blind, placebo-controlled study was undertaken. This study group consisted of 106 Chinese hypertensive subjects with diastolic blood pressure between 95 and 110 mmHg and ages ranging from 28 to 75 years with 60 subjects (men 34, women 26; mean t s.d., 54.1t3.8 years) allocated to active treatment and 46 (men 19, women 27; mean t s.d., 53.7t4.1 years) to placebo treatment. Each subject was given capsules containing stevioside (250 mg) or placebo thrice daily and followed-up at monthly intervals for 1 year. Results After 3 months, the systolic and diastolic blood pressure of the stevioside group decreased significantly (systolic: 166.0t9.4‐152.6t6.8 mmHg; diastolic: 104.7t5.2‐90.3t3.6 mmHg, P<0.05), and the effect persisted during the whole year. Blood biochemistry parameters including lipid and glucose showed no significant changes. No significant adverse effect was observed and quality of life assessment showed no deterioration. Conclusions This study shows that oral stevioside is a well tolerated and effective modality that may be considered as an alternative or supplementary therapy for patients with hypertension.
Paul K S Chan - One of the best experts on this subject based on the ideXlab platform.
-
a double blind placebo controlled study of the effectiveness and tolerability of oral stevioside in human hypertension
British Journal of Clinical Pharmacology, 2001Co-Authors: Paul K S Chan, Brian Tomlinson, Ming Hsiung Hsieh, Yi Jen Chen, Juei-tang ChengAbstract:Aims Stevioside is a natural Plant Glycoside isolated from the Plant Stevia rebaudiana which has been commercialized as a sweetener in Japan for more than 20 years. Previous animal studies have shown that stevioside has an antihypertensive effect. This study was to designed to evaluate the effect of stevioside in human hypertension. Methods A multicentre, randomized, double-blind, placebo-controlled study was undertaken. This study group consisted of 106 Chinese hypertensive subjects with diastolic blood pressure between 95 and 110 mmHg and ages ranging from 28 to 75 years with 60 subjects (men 34, women 26; mean t s.d., 54.1t3.8 years) allocated to active treatment and 46 (men 19, women 27; mean t s.d., 53.7t4.1 years) to placebo treatment. Each subject was given capsules containing stevioside (250 mg) or placebo thrice daily and followed-up at monthly intervals for 1 year. Results After 3 months, the systolic and diastolic blood pressure of the stevioside group decreased significantly (systolic: 166.0t9.4‐152.6t6.8 mmHg; diastolic: 104.7t5.2‐90.3t3.6 mmHg, P<0.05), and the effect persisted during the whole year. Blood biochemistry parameters including lipid and glucose showed no significant changes. No significant adverse effect was observed and quality of life assessment showed no deterioration. Conclusions This study shows that oral stevioside is a well tolerated and effective modality that may be considered as an alternative or supplementary therapy for patients with hypertension.
-
a double blind placebo controlled study of the effectiveness and tolerability of oral stevioside in human hypertension
British Journal of Clinical Pharmacology, 2001Co-Authors: Paul K S Chan, Brian Tomlinson, Ming Hsiung Hsieh, Yi Jen Chen, Juei-tang ChengAbstract:Aims Stevioside is a natural Plant Glycoside isolated from the Plant Stevia rebaudiana which has been commercialized as a sweetener in Japan for more than 20 years. Previous animal studies have shown that stevioside has an antihypertensive effect. This study was to designed to evaluate the effect of stevioside in human hypertension. Methods A multicentre, randomized, double-blind, placebo-controlled study was undertaken. This study group consisted of 106 Chinese hypertensive subjects with diastolic blood pressure between 95 and 110 mmHg and ages ranging from 28 to 75 years with 60 subjects (men 34, women 26; mean t s.d., 54.1t3.8 years) allocated to active treatment and 46 (men 19, women 27; mean t s.d., 53.7t4.1 years) to placebo treatment. Each subject was given capsules containing stevioside (250 mg) or placebo thrice daily and followed-up at monthly intervals for 1 year. Results After 3 months, the systolic and diastolic blood pressure of the stevioside group decreased significantly (systolic: 166.0t9.4‐152.6t6.8 mmHg; diastolic: 104.7t5.2‐90.3t3.6 mmHg, P<0.05), and the effect persisted during the whole year. Blood biochemistry parameters including lipid and glucose showed no significant changes. No significant adverse effect was observed and quality of life assessment showed no deterioration. Conclusions This study shows that oral stevioside is a well tolerated and effective modality that may be considered as an alternative or supplementary therapy for patients with hypertension.
Liangcai Peng - One of the best experts on this subject based on the ideXlab platform.
-
overproduction of native endo β 1 4 glucanases leads to largely enhanced biomass saccharification and bioethanol production by specific modification of cellulose features in transgenic rice
Biotechnology for Biofuels, 2019Co-Authors: Jiangfeng Huang, Tao Xia, Yanting Wang, Youmei Wang, Yuanyuan Chen, Guosheng Xie, Fengwu Bai, Liangcai PengAbstract:Genetic modification of Plant cell walls has been implemented to reduce lignocellulosic recalcitrance for biofuel production. Plant Glycoside hydrolase family 9 (GH9) comprises endo-β-1,4-glucanase in Plants. Few studies have examined the roles of GH9 in cell wall modification. In this study, we independently overexpressed two genes from GH9B subclasses (OsGH9B1 and OsGH9B3) and examined cell wall features and biomass saccharification in transgenic rice Plants. Compared with the wild type (WT, Nipponbare), the OsGH9B1 and OsGH9B3 transgenic rice Plants, respectively, contained much higher OsGH9B1 and OsGH9B3 protein levels and both proteins were observed in situ with nonspecific distribution in the Plant cells. The transgenic lines exhibited significantly increased cellulase activity in vitro than the WT. The OsGH9B1 and OsGH9B3 transgenic Plants showed a slight alteration in three wall polymer compositions (cellulose, hemicelluloses, and lignin), in their stem mechanical strength and biomass yield, but were significantly decreased in the cellulose degree of polymerization (DP) and lignocellulose crystalline index (CrI) by 21–22%. Notably, the crude cellulose substrates of the transgenic lines were more efficiently digested by cellobiohydrolase (CBHI) than those of the WT, indicating the significantly increased amounts of reducing ends of β-1,4-glucans in cellulose microfibrils. Finally, the engineered lines generated high sugar yields after mild alkali pretreatments and subsequent enzymatic hydrolysis, resulting in the high bioethanol yields obtained at 22.5% of dry matter. Overproduction of OsGH9B1/B3 enzymes should have specific activity in the postmodification of cellulose microfibrils. The increased reducing ends of β-1,4-glucan chains for reduced cellulose DP and CrI positively affected biomass enzymatic saccharification. Our results demonstrate a potential strategy for genetic modification of cellulose microfibrils in bioenergy crops.
Ming Hsiung Hsieh - One of the best experts on this subject based on the ideXlab platform.
-
a double blind placebo controlled study of the effectiveness and tolerability of oral stevioside in human hypertension
British Journal of Clinical Pharmacology, 2001Co-Authors: Paul K S Chan, Brian Tomlinson, Ming Hsiung Hsieh, Yi Jen Chen, Juei-tang ChengAbstract:Aims Stevioside is a natural Plant Glycoside isolated from the Plant Stevia rebaudiana which has been commercialized as a sweetener in Japan for more than 20 years. Previous animal studies have shown that stevioside has an antihypertensive effect. This study was to designed to evaluate the effect of stevioside in human hypertension. Methods A multicentre, randomized, double-blind, placebo-controlled study was undertaken. This study group consisted of 106 Chinese hypertensive subjects with diastolic blood pressure between 95 and 110 mmHg and ages ranging from 28 to 75 years with 60 subjects (men 34, women 26; mean t s.d., 54.1t3.8 years) allocated to active treatment and 46 (men 19, women 27; mean t s.d., 53.7t4.1 years) to placebo treatment. Each subject was given capsules containing stevioside (250 mg) or placebo thrice daily and followed-up at monthly intervals for 1 year. Results After 3 months, the systolic and diastolic blood pressure of the stevioside group decreased significantly (systolic: 166.0t9.4‐152.6t6.8 mmHg; diastolic: 104.7t5.2‐90.3t3.6 mmHg, P<0.05), and the effect persisted during the whole year. Blood biochemistry parameters including lipid and glucose showed no significant changes. No significant adverse effect was observed and quality of life assessment showed no deterioration. Conclusions This study shows that oral stevioside is a well tolerated and effective modality that may be considered as an alternative or supplementary therapy for patients with hypertension.
-
a double blind placebo controlled study of the effectiveness and tolerability of oral stevioside in human hypertension
British Journal of Clinical Pharmacology, 2001Co-Authors: Paul K S Chan, Brian Tomlinson, Ming Hsiung Hsieh, Yi Jen Chen, Juei-tang ChengAbstract:Aims Stevioside is a natural Plant Glycoside isolated from the Plant Stevia rebaudiana which has been commercialized as a sweetener in Japan for more than 20 years. Previous animal studies have shown that stevioside has an antihypertensive effect. This study was to designed to evaluate the effect of stevioside in human hypertension. Methods A multicentre, randomized, double-blind, placebo-controlled study was undertaken. This study group consisted of 106 Chinese hypertensive subjects with diastolic blood pressure between 95 and 110 mmHg and ages ranging from 28 to 75 years with 60 subjects (men 34, women 26; mean t s.d., 54.1t3.8 years) allocated to active treatment and 46 (men 19, women 27; mean t s.d., 53.7t4.1 years) to placebo treatment. Each subject was given capsules containing stevioside (250 mg) or placebo thrice daily and followed-up at monthly intervals for 1 year. Results After 3 months, the systolic and diastolic blood pressure of the stevioside group decreased significantly (systolic: 166.0t9.4‐152.6t6.8 mmHg; diastolic: 104.7t5.2‐90.3t3.6 mmHg, P<0.05), and the effect persisted during the whole year. Blood biochemistry parameters including lipid and glucose showed no significant changes. No significant adverse effect was observed and quality of life assessment showed no deterioration. Conclusions This study shows that oral stevioside is a well tolerated and effective modality that may be considered as an alternative or supplementary therapy for patients with hypertension.